| 2.27 0.07 (3.18%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.22 | 1-year : | 3.66 |
| Resists | First : | 2.75 | Second : | 3.14 |
| Pivot price | 2.56  |
|||
| Supports | First : | 2.14 | Second : | 1.78 |
| MAs | MA(5) : | 2.32 |
MA(20) : | 2.62 |
| MA(100) : | 2.62  |
MA(250) : | 2.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 7.2 |
| RSI | RSI(14): 33.5 |
|||
| 52-week | High : | 5.25 | Low : | 1.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORMP ] has closed above bottom band by 12.0%. Bollinger Bands are 33.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.32 | 2.32 - 2.33 |
| Low: | 2.15 - 2.16 | 2.16 - 2.18 |
| Close: | 2.24 - 2.27 | 2.27 - 2.3 |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Mon, 15 Apr 2024
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 20.6% in March - MarketBeat
Fri, 12 Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years - Yahoo Movies Canada
Mon, 18 Mar 2024
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners - TipRanks.com - TipRanks
Tue, 20 Feb 2024
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy - TipRanks.com - TipRanks
Tue, 20 Feb 2024
Oramed Letter to Shareholders - PR Newswire
Fri, 02 Feb 2024
Top 4 Health Care Stocks That May Crash This Quarter - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 3.67e+007 (%) |
| Held by Institutions | 11.2 (%) |
| Shares Short | 501 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.557e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 412.3 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 176.7 % |
| Return on Equity (ttm) | -5.2 % |
| Qtrly Rev. Growth | 1.34e+006 % |
| Gross Profit (p.s.) | -54.95 |
| Sales Per Share | 1.78 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.27 |
| Price to Cash Flow | 1.01 |
| Dividend | 0 |
| Forward Dividend | 583940 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|